Icon (NASDAQ:ICLR – Get Free Report) and CryoPort (NASDAQ:CYRX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.
Institutional and Insider Ownership
95.6% of Icon shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 9.5% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Icon has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
Valuation and Earnings
This table compares Icon and CryoPort”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Icon | $8.25 billion | 1.56 | $229.34 million | $4.26 | 39.47 |
| CryoPort | $176.18 million | 4.88 | $78.30 million | ($0.90) | -18.87 |
Icon has higher revenue and earnings than CryoPort. CryoPort is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Icon and CryoPort’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Icon | 3.99% | 8.02% | 4.56% |
| CryoPort | -20.05% | -7.20% | -4.30% |
Analyst Ratings
This is a breakdown of current recommendations for Icon and CryoPort, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icon | 1 | 9 | 7 | 1 | 2.44 |
| CryoPort | 0 | 2 | 8 | 0 | 2.80 |
Icon presently has a consensus target price of $174.73, indicating a potential upside of 3.92%. CryoPort has a consensus target price of $19.33, indicating a potential upside of 13.86%. Given CryoPort’s stronger consensus rating and higher possible upside, analysts clearly believe CryoPort is more favorable than Icon.
Summary
Icon beats CryoPort on 10 of the 15 factors compared between the two stocks.
About Icon
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
About CryoPort
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
